ENTRY       D06657                      Drug
NAME        Tremelimumab (USAN/INN);
            Tremelimumab (genetical recombination) (JAN);
            Tremelimumab-actl;
            CP 675206;
            Imjudo (TN)
PRODUCT     IMJUDO (AstraZeneca Pharmaceuticals LP)
FORMULA     C6500H9974N1726O2026S52
EXACT_MASS  146289.5973
MOL_WEIGHT  146380.4722
SEQUENCE    (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Heavy chain)
            QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY
            ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTT
            VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA
            GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF
            NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE
            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR
            WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
            (Disulfide bridge: L23-L88, L134-L194, L214-H139, H22-H96, H152-H208, H265-H325, H371-H429, H227-H'227, H228-H'228, H231-H'231, H234-H'234)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FX20
            Product: D06657<JP/US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody
  DISEASE   Hepatocellular carcinoma [DS:H00048]
            Non-small cell lung cancer [DS:H00014]
  TYPE      Monoclonal antibody
COMMENT     Treatment of melanoma
TARGET      CTLA4 (CD152) [HSA:1493] [KO:K06538]
  PATHWAY   hsa04514(1493)  Cell adhesion molecules
            hsa04660(1493)  T cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX20 Tremelimumab
                  D06657  Tremelimumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Tremelimumab
                D06657  Tremelimumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D06657  Tremelimumab (USAN/INN); Tremelimumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D06657  Tremelimumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D06657  Tremelimumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                CTLA4 (CD152)
                 D06657  Tremelimumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06657
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06657
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06657
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06657
DBLINKS     CAS: 745013-59-6
            PubChem: 47208308
///
